麻豆社

The Association of the British Pharmaceutical Industry (ABPI) has welcomed measures in Chancellor Jeremy Hunt鈥檚 Budget to unlock investment in medical research and medicines manufacturing and improve NHS productivity.

Pharmaceutical manufacturing alone is responsible for 拢16.4 billion in GVA to the UK economy each year. By delivering a supportive policy and operating environment for medicines manufacturing, the UK could attract 拢15 billion worth of investment and create an additional 26,500 jobs over the next ten years [1].

Today this potential was demonstrated with the Chancellor pointing to a new 拢650 million investment by AstraZeneca into sites in Cambridge and Speke near Liverpool.

Also in the Budget was 拢45 million for charitable medical research, and 拢3.4 billion for NHS digital infrastructure to improve productivity.

Richard Torbett, Chief Executive of the ABPI, said: 鈥淭he UK鈥檚 life sciences industry continues to be one of the country鈥檚 highest potential growth sectors 鈥� and it is great to see some of that potential demonstrated today. AstraZeneca鈥檚 investment shows that if we get the policy environment right, we can reinvigorate medicine manufacturing in this country, creating new jobs and prosperity across the country.

鈥淥ur members will also welcome the support announced today which will improve the wider UK medical and life sciences ecosystem, including the support for UK charitable medical research and more money for NHS digital transformation.鈥�